Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
Veronika Bachanová, Sarah Cooley, Todd E. DeFor, et al.
Blood (2014) Vol. 123, Iss. 25, pp. 3855-3863
Open Access | Times Cited: 385

Showing 1-25 of 385 citing articles:

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu H. Estey, David Grimwade, et al.
Blood (2016) Vol. 129, Iss. 4, pp. 424-447
Open Access | Times Cited: 5121
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey, Nicholas D. Huntington, Mark J. Smyth
Nature Immunology (2016) Vol. 17, Iss. 9, pp. 1025-1036
Closed Access | Times Cited: 977
NK cells for cancer immunotherapy
Noriko Shimasaki, Amit Jain, Dario Campana
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 3, pp. 200-218
Closed Access | Times Cited: 959
Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers, Jeffrey S. Miller
Nature Reviews Clinical Oncology (2020) Vol. 18, Iss. 2, pp. 85-100
Open Access | Times Cited: 908
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li, David Hermanson, Branden S. Moriarity, et al.
Cell stem cell (2018) Vol. 23, Iss. 2, pp. 181-192.e5
Open Access | Times Cited: 787
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee, Maximillian Rosario, Melissa M. Berrien-Elliott, et al.
Science Translational Medicine (2016) Vol. 8, Iss. 357
Open Access | Times Cited: 742
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee, Sarah Cooley, Melissa M. Berrien-Elliott, et al.
Blood (2018) Vol. 131, Iss. 23, pp. 2515-2527
Open Access | Times Cited: 357
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence,In VivoExpansion, and Enhanced Function
Daniel A. Vallera, Martin Felices, Ron McElmurry, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 14, pp. 3440-3450
Open Access | Times Cited: 323
The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists
Sunil Thomas, Jacques Izard, Emily Walsh, et al.
Cancer Research (2017) Vol. 77, Iss. 8, pp. 1783-1812
Open Access | Times Cited: 312
NK cell-based immunotherapy for cancer
Fang Fang, Weihua Xiao, Zhigang Tian
Seminars in Immunology (2017) Vol. 31, pp. 37-54
Closed Access | Times Cited: 277
Natural killer cell-mediated immunosurveillance of human cancer
Karl‐Johan Malmberg, Mattias Carlsten, Andreas T. Björklund, et al.
Seminars in Immunology (2017) Vol. 31, pp. 20-29
Closed Access | Times Cited: 255
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Katayoun Rezvani, Rayne H. Rouce
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 248
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta, Katayoun Rezvani
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 232
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Richard W. Childs, Mattias Carlsten
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 7, pp. 487-498
Closed Access | Times Cited: 221
Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation
Nirali N. Shah, Kristin Baird, Cynthia Delbrook, et al.
Blood (2014) Vol. 125, Iss. 5, pp. 784-792
Open Access | Times Cited: 216
Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
Mattias Carlsten, Richard W. Childs
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 213
Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Zhu Huang, Robert Blum, Ryan Bjordahl, et al.
Blood (2019) Vol. 135, Iss. 6, pp. 399-410
Open Access | Times Cited: 212
NK cells regulating T cell responses: mechanisms and outcome
Josh Crouse, Haifeng C. Xu, Philipp A. Lang, et al.
Trends in Immunology (2014) Vol. 36, Iss. 1, pp. 49-58
Closed Access | Times Cited: 210
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives
Cristiana Lo Nigro, Marco Macagno, Dario Sangiolo, et al.
Annals of Translational Medicine (2019) Vol. 7, Iss. 5, pp. 105-105
Open Access | Times Cited: 202
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
Sarah Cooley, Fiona He, Veronika Bachanová, et al.
Blood Advances (2019) Vol. 3, Iss. 13, pp. 1970-1980
Open Access | Times Cited: 192
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy
Frank Cichocki, Ryan Bjordahl, Svetlana Gaidarova, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 568
Open Access | Times Cited: 191
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
John P. Veluchamy, Nina Kok, Hans van Vliet, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 178
Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation
Federico Simonetta, Maite Álvarez, Robert S. Negrin
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 174
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Dhifaf Sarhan, Frank Cichocki, Bin Zhang, et al.
Cancer Research (2016) Vol. 76, Iss. 19, pp. 5696-5706
Open Access | Times Cited: 173
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, et al.
Clinical Cancer Research (2017) Vol. 24, Iss. 7, pp. 1525-1535
Open Access | Times Cited: 172
Page 1 - Next Page

Scroll to top